LXRX | Lexicon Pharmaceuticals, Inc. Stock Overview

(Stock Exchange: NASDAQ)

Day's Range	1.5600 - 1.6600
52 Week Range	0.9200 - 3.73
Beta	1.37
Implied Volatility	101.54%
IV Rank	39.93%
Day's Volume	3,450,528
Average Volume	2,928,456
Shares Outstanding	361,492,000
Market Cap	582,002,120
Sector	Healthcare
Industry	Biotechnology
IPO Date	2000-04-07

Valuation
Profitability
Growth
Health
P/E Ratio	-2.06
Forward P/E Ratio	N/A
EPS	-0.78
1YR Price Target	N/A
Dividend Yield	N/A
Dividend Per Share	N/A
Dividend ExDate	N/A
Dividend PayDate	N/A
Employees	285
Country	USA
Website	LXRX

Lexicon Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical products. Its orally-delivered small molecule drug candidates under development comprise Sotagliflozin that completed Phase III clinical trials for the for the treatment of heart failure and type 1 diabetes; and LX9211, which is in Phase II clinical development for the treatment of neuropathic pain. The company has strategic collaboration and license agreements with Bristol-Myers Squibb Company, and Genentech, Inc. Lexicon Pharmaceuticals, Inc. was incorporated in 1995 and is headquartered in The Woodlands, Texas.

LXRX's peers: ALDX, ARDX, BLRX, CTXR, EYEN, IBRX, MCRB, EFTR, XFOR, ELEV, MREO, HEPA, GRTX, TERN, DAWN, HOOK, ENVB, CWBR, OCEA, AVRO, ORMP, PLX, VERU

*Chart delayed

Analyzing fundamentals for LXRX we got that it has weak fundamentals where Valuation is considered to be significantly overvalued, Profitability is unacceptably poor, Growth is bad and Health is weak. For more detailed analysis please see LXRX Fundamentals page.

Watching at LXRX technicals we can see that long-term trend is bearish, the same as bearish middle-term trend, as well as bearish short-term trend. More technicals details can be found on LXRX Technicals page.